Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Diabetes Prevention Through Genetics, Familial History and Behavior Change

6 de setembro de 2026 atualizado por: Candice Alick, PhD, Morehouse School of Medicine

Legacy-DPP: Diabetes Prevention Through Genetics, Familial History and Behavior Change A Family-Enhanced, Genetically-Informed Diabetes Prevention Program

The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health.

The main questions it aims to answer are:

  • Does adding family health history collection and family participation to the DPP improve session attendance compared to standard DPP?
  • Does this family-centered approach lead to greater weight loss and HbA1c (blood sugar) reduction compared to standard DPP?
  • Do health improvements extend to participants' family members, and what factors explain differences in family-level outcomes?

Researchers will compare an adapted DPP with a family component to the standard DPP (individual-focused) to see if involving family members improves diabetes prevention outcomes.

Participants will:

  • Be assigned to one of two groups: adapted DPP with family sessions, or standard DPP
  • If assigned to the adapted DPP, complete a family health history using the CDC's My Family Health Portrait tool and attend 6 additional sessions with family members focused on personalized risk communication
  • Attend regular checkups to measure weight and HbA1c at 6 and 12 months
  • Have session attendance tracked throughout the program
  • Family members of participants may also be asked to complete health assessments to measure any changes in their own health behaviors

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Type 2 diabetes affects 38.4 million U.S. adults, and an additional 97.6 million adults have prediabetes and are at risk of developing the disease. This burden falls disproportionately on racial and ethnic minority families and rural communities.

This clinical trial aims to determine whether embedding family engagement and family health history into the Diabetes Prevention Program (DPP) improves adherence, weight loss, and glycemic outcomes among adults with prediabetes, compared to the standard individual-focused DPP.

Participants will be 200 index participants with prediabetes, along with their family members, recruited from rural and urban sites and stratified by geographic location. Index participants will be block randomized to receive either standard DPP or an adapted version that adds 6 weeks of family health history and genetics education-using the CDC's My Family Health Portrait tool-paired with family participation and skill-building sessions.

All participants will attend regular clinic visits to monitor weight and HbA1c at 6 and 12 months and will have session attendance tracked throughout. Family members will also complete health assessments to measure whether health improvements extend beyond the index participant, and researchers will use the Actor-Partner Interdependence Model to identify factors explaining variation in family-level outcomes.

This is a 2-arm randomized controlled trial comparing standard DPP to a family-adapted DPP incorporating family health history, genetics education, and family skill-building.

Tipo de estudo

Intervencional

Inscrição (Estimado)

400

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Candice L Alick, PhD
  • Número de telefone: 404-752-1009
  • E-mail: calick@msm.edu

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Age ≥18 years.
  • Fasting HbA1c 5.7-6.4% confirmed by CLIA-waived point-of-care testing.
  • BMI ≥25 kg/m².
  • Able to provide informed consent.
  • Has an adult household/family or framily (fictive kin) member willing to enroll as a paired participant.
  • Willing to attend in-person sessions

Exclusion Criteria:

  • Minors <18 years
  • Prior diagnosis of T1 or T2D.
  • HbA1c ≥6.5% at screening (Aim 1/2 curriculum eligibility)
  • Current glucose-lowering medication use
  • Pregnancy
  • Physical-activity contraindications
  • Individuals unable to speak or understand English

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Lifestyle Engagement through Genetics and Collaborative familY DPP (LEGACY DPP)
Participants will receive the LEGACY DPP intervention

The index partner will participate in an adapted DPP as a dyad with a family member with family health history and family participation and skill building

Participants will receive

  • family health history sessions
  • core behavioral weight loss group sessions
  • a family skill building segment covering cohesion and communication during core sessions
Comparador Ativo: Diabetes Prevention Program (DPP)
Participants will receive the DPP intervention

The index partner will participate in standard DPP

Participants will receive

- core behavioral weight loss group sessions

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percent change in body weight
Prazo: Baseline, 6 months, 12 months
Body weight (kg) expressed as a continuous variable will be collected on a digital scale.
Baseline, 6 months, 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mean Change in Blood Pressure
Prazo: Baseline, 6 months, 12 months
Blood Pressure measured after 5 minutes of rest and taken in the same position throughout the study.
Baseline, 6 months, 12 months
Change in HbA1c (fasting, CLIA-waived assay)
Prazo: Baseline, 6 months, 12 months
Blood (~20 mL) will be collected to assess changes in glycosloated hemoglobin
Baseline, 6 months, 12 months
Change in Fasting lipid panel (total cholesterol, HDL, LDL, triglycerides)
Prazo: Baseline, 6 months, 12 months
Fasting lipid panel will measured to assess changes in total cholesterol, HDL, LDL, and triglycerides.
Baseline, 6 months, 12 months
Change in Skin carotenoids
Prazo: Baseline, 6 months, 12 months
Skin carotenoids will be assessed using a VeggieMeter as an indicator for fruit and vegetable intake.
Baseline, 6 months, 12 months
Change in Physical activity steps
Prazo: Baseline, 6 months, 12 months
Steps will be measured using an activity tracker e.g., Fitbit
Baseline, 6 months, 12 months
Change in Self-Regulation of Eating Behaviors
Prazo: Baseline, 6 months, 12 months
The Eating Behavior Inventory (20 items) measures the adoption of eating behaviors associated with weight loss (e.g., monitoring quantity eaten, frequency of weighing, shopping from a list) to measure self-regulation behaviors. Items are rated on a 5-point frequency scale from "never or hardly ever" to "always or almost always." Scores range from 26 to 130
Baseline, 6 months, 12 months
Change in Self-Efficacy of Eating Behaviors
Prazo: Baseline, 6 months, 12 months
Measured by survey responses to the Weight Efficacy Lifestyle Questionnaire Short Form (WEL-SF).Scale goes from 0 (not at all confident) to 10 (very confident). Higher scores mean better self efficacy.
Baseline, 6 months, 12 months
Change in Self-Efficacy of Physical Activity
Prazo: Baseline, 6 months, 12 months
The confidence subscale of the Patient-centered Assessment and Counseling for Exercise Adult Diet and Physical Activity Measure (6 items; ) measures confidence in participating in regular exercise or physical activity in different situations (e.g., "How confident are you that you would participate in regular exercise or physical activity: When I am tired?"). Items rated on a scale from 1 ("not at all confident") to 6 ("extremely confident"). Higher scores show higher self-efficacy.
Baseline, 6 months, 12 months
Change in Social Support for Eating
Prazo: Baseline, 6 months, 12 months
The Social Support and Eating Habits Survey (10 items) measures social support specific to healthy eating. Subscales assess encouragement for eating behaviors from partners (e.g., "Encouraged me not to eat 'unhealthy food' when I am tempted") and discouragement for eating behaviors from partners (e.g., "Brought home foods I am trying not to eat"). The items are rated on a scale of "none" to "very often." Total scores range from 5 to 50, with higher scores indicating more social support for eating behaviors.
Baseline, 6 months, 12 months
Change in Social Support for Exercise
Prazo: Baseline, 6 months, 12 months
The exercise participation subscale of the Social Support and Exercise Survey (10 items) measures social support specific to exercise behaviors. The subscale assesses the level of support for exercise from partners. Subscale example items include "Exercised with me" and "Criticized or made fun of me for exercising." Total scores range from 5 to 50, with higher scores indicating more social support for exercise participation behaviors.
Baseline, 6 months, 12 months
Change in Family Communication
Prazo: Baseline, 6 months, 12 months
Family communication is assessed with the communication subscale of the McMaster Family Assessment Device (6 items). Communication is defined as the exchange of information among family members. Items focused on whether verbal messages were clear and direct for the intended recipient. Responses ranged from "strongly agree" to "strongly disagree." Higher scores represent unhealthy communication.
Baseline, 6 months, 12 months
Change in Family Cohesion
Prazo: Baseline, 6 months, 12 months
The cohesion subscale (10 items) of the Family Adaptability and Cohesion Evaluation Scale III measures the emotional bonding family members have with one another. Items like "Family members ask each other for help" rated on a 5-point Likert scale from "almost never" to "almost always."
Baseline, 6 months, 12 months
Change in Family Emotional Involvement
Prazo: Baseline, 6 months, 12 months
The family emotional involvement (7 items) of the Family Emotional Involvement and Criticism Scale rate items on a 5-point Likert scale, as above.
Baseline, 6 months, 12 months
Change in Family Perceived Criticism
Prazo: Baseline, 6 months, 12 months
The perceived criticism (7 items) subscales of the Family Emotional Involvement and Criticism Scale rate items like on a 5-point Likert scale, as above.
Baseline, 6 months, 12 months
Change in Family Collaborative problem solving
Prazo: Baseline, 6 months, 12 months
The Family Problem-Solving Communication Index (10 items) was used to measure the specific communication style that families use to manage and solve problems and conflicts in various types of stressful situations. Consisting of 2 subscales, affirmatory communication and incendiary communication, the response options were "false," "mostly false," "mostly true," and "true."
Baseline, 6 months, 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Candice L Alick, PhD, Morehouse School of Medicine
  • Investigador principal: Tennille Leak-Johnson, PhD, Morehouse School of Medicine

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

31 de janeiro de 2031

Conclusão do estudo (Estimado)

31 de janeiro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

6 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de setembro de 2026

Primeira postagem (Real)

11 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

11 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever